Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102

被引：0
|
作者：
Hamauchi, S. [1 ]
Yamazaki, K. [1 ]
Masuishi, T. [2 ]
Kito, Y. [1 ]
Komori, A. [2 ]
Tsushima, T. [1 ]
Todaka, A. [1 ]
Yokota, T. [1 ]
Machida, N. [1 ]
Fukutomi, A. [1 ]
Onozawa, Y. [3 ]
Muro, K. [2 ]
Yasui, H. [1 ]
Mori, K. [4 ]
Taniguchi, H. [2 ]
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Div Clin Oncol, Nagoya, Aichi 464, Japan
[3] Shizuoka Canc Ctr, Div Clin Oncol, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Clin Trial Coordinat Off, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
165P
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [41] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    [J]. CANCERS, 2023, 15 (13)
  • [42] TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
    Zaniboni, Alberto
    Bertocchi, Paola
    Barni, Sandro
    Petrelli, Fausto
    [J]. Clinical Colorectal Cancer, 2016, 15 (04) : 292 - 297
  • [43] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
  • [44] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer
    Kotani, D.
    Pashtoon, K.
    Cecchini, M.
    Shitara, K.
    Ohtsu, A.
    Ramanathan, R.
    Hochster, H.
    Grothey, A.
    Yoshino, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 105 - 105
  • [46] Colorectal Cancer TAS-102 effective with refractory Recurrence
    Franke, Katharina
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144
  • [47] Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.
    Ohtsu, Atsushi
    Yoshino, Takayuki
    Falcone, Alfredo
    Garcia-Carbonero, Rocio
    Argiles, Guillem
    Sobrero, Alberto F.
    Peeters, Marc
    Makris, Lukas
    Benedetti, Fabio
    Zaniboni, Alberto
    Shimada, Yasuhiro
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Hochster, Howard S.
    Lenz, Heinz-Josef
    Tran, Ben
    Wahba, Mona
    Yoshida, Kenichiro
    Van Cutsem, Eric
    Mayer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    [J]. LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [49] Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
    Jalali, A.
    Gard, G.
    Banks, S.
    Dunn, C.
    Wong, H. L.
    Wong, R.
    Lee, M.
    Gately, L.
    Loft, M.
    Shapiro, J. D.
    Kosmider, S.
    Tie, J.
    Ananda, S.
    Yeung, J. M.
    Jennens, R.
    Lee, B.
    McKendrick, J.
    Lim, L.
    Khattak, A.
    Gibbs, P.
    [J]. CURRENT PROBLEMS IN CANCER, 2022, 46 (02)
  • [50] Hospitalizations and clinical outcome in metastatic colorectal cancer during regorafenib or TAS-102 therapy
    Huemer, F.
    Piringer, G.
    Schlintl, V.
    Hackl, H.
    Rinnerthaler, G.
    Thaler, J.
    Greil, R.
    Weiss, L.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 128 - 128
12345